Crossmark

La ampliación de criterios de administración de palivizumab no disminuye los ingresos por virus respiratorio sincitial

Crossref DOI link: https://doi.org/10.1016/j.vacun.2023.10.007

Published Print: 2024-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Gómez Ávila, Jessica

Iñigo Gil, Juan

Flores Méndez, Beatriz
License Information

Text and Data Mining valid from 2024-01-01

stm-asf valid from 2024-01-01

stm-asf valid from 2024-01-01

stm-asf valid from 2024-01-01

stm-asf valid from 2024-01-01

stm-asf valid from 2024-01-01
More Information

This article is maintained by: Elsevier

Article Title: La ampliación de criterios de administración de palivizumab no disminuye los ingresos por virus respiratorio sincitial

Journal Title: Vacunas

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.vacun.2023.10.007

Content Type: article

Copyright: © 2023 Elsevier España, S.L.U. All rights reserved.